Rheumatology is a field rife with uncertainty. With regard to both diagnosis and treatment, we live in a world of rare diseases that are difficult to study. As a result, we are often left without an answer to our diagnostic dilemmas and without clarity when deciding the best treatment options for our patients. For rheumatologists…
“Congratulations! You have matched!” With Match Day in the rearview mirror and residency nearing an end, incoming fellows prepare for the next road trip on their journey to becoming a rheumatologist. Residency molds new graduates into competent physicians by providing an overview of general medicine and teaching them the clinical and professional skills necessary to…
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…
Designed in the TED Talk style, In the Rheum sessions will feature the hottest topics and biggest scientific takeaways for rheumatology using a shorter, more casual approach during the 2019 ACR/ARP Annual Meeting…
Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
With her combined expertise in rheumatology and informatics, Dr. Yazdany is leading the ACR’s Registries and Health Information Technology Committee to create a national health IT infrastructure that advances rheumatology practice.
Secukinumab therapy proved safe and effective for psoriatic arthritis patients with multiple co-morbidities and long treatment histories, according to recent research…
The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
An analysis of follow-up data from the DESIR cohort showed patients with recent onset axial spondyloarthritis who experienced peripheral arthritis had worse symptoms and quality of life long term. In the study, peripheral arthritis was also associated with negative HLAB27, non-smoking and the presence of other peripheral disease manifestations…